MEREO BIOPHARMA GROUP PLC Financial Liabilities Carrying Amount Immediately Before Initial Application Of IFRS9
MEREO BIOPHARMA GROUP PLC (MREO) had Financial Liabilities Carrying Amount Immediately Before Initial Application Of IFRS9 of GBP 1.98 million as of 2018-01-01, per its 20-F/A filed 2019-05-29.
Discontinued › Notes
ifrs-full:FinancialLiabilitiesCarryingAmountImmediatelyBeforeInitialApplicationOfIFRS9 · last filed 2020-06-15
- 2018-01-01: Financial Liabilities Carrying Amount Immediately Before Initial Application Of IFRS9 1.98M GBP.
- 2017-12-31: Financial Liabilities Carrying Amount Immediately Before Initial Application Of IFRS9 1.98M GBP.
| Period end | Financial Liabilities Carrying Amount Immediately Before Initial Application Of IFRS9 |
|---|---|
| 2018-01-01 | 1.98M GBP 20-F/A · filed 2019-05-29 |
| 2017-12-31 | 1.98M GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |